Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enasidenib and Cobimetinib in R/R AML with IDH2 and RAS Mutations
NCT05441514Phase 1Completed
- Sponsor
- City of Hope
- Start
- Apr 2023
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cobimetinib and enasidenib in acute myeloid leukemia (AML), sponsored by City of Hope. Primary endpoints: Dose Limiting Toxicity at 28 days and Adverse Events. Started Apr 2023; status: completed.
02
Drugs
cobimetinibenasidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05441514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05441514.